Classification
ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions
ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management
Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal
Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement
FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce
FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy
Gilead hops straight to Phase III with once-yearly HIV PrEP shot
PREP gene, formulations, once-yearly, Trial Phase
Challenges in Moving Pharmaceutical Manufacturing to the US
Bavarian Nordic, pharmaceutical manufacturing, US relocation, time constraints, infrastructure limitations
Medtronic Launches Adaptive Brain Stimulation for Parkinson’s Disease Following EU Approval
Medtronic, BrainSense, Adaptive Deep Brain Stimulation, Parkinson’s Disease, EU Approval, CE Mark
FDA Approves Voranigo, the First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Voranigo, FDA approval, targeted therapy, Grade 2 IDH-mutant glioma, brain tumor, Servier Pharmaceuticals, IDH1/IDH2 inhibitor
Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial
Antibodies, Trial Phase, Urticaria, chronic hives
Biden Ramps Up Fight Against High Drug Prices in State of the Union Address
State of the Union Address, Biden Administration, Big Pharma, Drug Prices, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private Insurance Protections, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy Access Model, Commercial Drug Sales Rebates